Comparative Pharmacology
Head-to-head clinical analysis: GVS versus TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus TOBRAMYCIN.
GVS vs TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death. Exhibits concentration-dependent bactericidal activity.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
5-7 mg/kg IV once daily; 2-4 mg/kg/day IV divided every 8 hours for synergy; 2-4 mg/kg IM divided every 8 hours; 3-5 mg/kg/day IV for cystic fibrosis. Inhalation: 300 mg every 12 hours (nebulizer). Intrathecal: 5-20 mg/day.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateTobramycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Acetyldigitoxin
2–3 hours (normal renal function); prolonged to 24–60 hours in anuria. Clinical context: dosing interval must be adjusted for renal impairment to avoid accumulation and toxicity.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Renal excretion of unchanged drug via glomerular filtration: >90% within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Tobramycin."